R&D News | pharmaphorum

News

MorphoSys shrugs off mixed results for myelofibrosis drug

MorphoSys has said it will press ahead with regulatory filings for its myelofibrosis drug candidate pelabresib, despite mixed results in a phase 3 trial.

News

MSD reaches $610m deal to buy lysosome biotech Caraway

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.

News

GSK says new inhaler will help slash its carbon footprint

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly hal

News

Oxurion files for bankruptcy as DME drug fails

The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint.

News

AZ launches digital clinical trials business

AstraZeneca has launched a separate business unit that will take what the drugmaker has learned from running digitally-powered clinical trials and offer that experience to

News

Bayer pulls atrial fibrillation study for asundexian

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded

MorphoSys shrugs off mixed results for myelofibrosis drug

MSD reaches $610m deal to buy lysosome biotech Caraway

GSK says new inhaler will help slash its carbon footprint

Oxurion files for bankruptcy as DME drug fails

AZ launches digital clinical trials business

Bayer pulls atrial fibrillation study for asundexian

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks